Market Announcement



2 February 2024

Imricor Medical Systems, Inc. (ASX: IMR) – Suspension from Quotation

Description

The securities of Imricor Medical Systems, Inc. ('IMR') will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMR, pending the release of an announcement regarding a proposed capital raising.

Issued by

ASX Compliance



2 February 2024

Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) South Tower, Level 50, 525 Collins Street Melbourne VIC 3000

By email only: melissa.kostopoulos@asx.com.au; tradinghaltsmelbourne@asx.com.au

Dear Ms Kostopoulos

REQUEST FOR VOLUNTARY SUSPENSION

Imricor Medical Systems, Inc. (ASX: **IMR**) (the **Company**) requests an immediate voluntary suspension to the trading of the Company's ordinary shares quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending an announcement to be made by the Company to the market in relation to an update in connection with a proposed capital raising.

In accordance with Listing Rule 17.2, the Company provides the following information in relation to the request:

- 1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to a proposed capital raising.
- 2. The Company requests that voluntary suspension remains in place until commencement of normal trading on Monday, 5 February 2024.
- 3. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely By order of the Board of Imricor Medical Systems, Inc.

Kobe Li Company Secretary